Hamps Bio Limited (BSE SME)

Dec 13, 2024 - Dec 17, 2024

Price ₹51 - ₹51
Premium ₹60
Lot size 2000
Allotment Dec 18, 2024
Listing Dec 20, 2024
Category Lot(s) Qty Amount Reserved
Retail 1 2000 102000 290
HNI 2 4000 204000 289

Last updated on 17-Dec-2024 18:08:00

CategoryOfferedAppliedTimes
HNIs578000447032000773.41
Retail5800007770420001339.73
Total115800012161400001050.21
Total Applications: 665948
HNI Interest Cost Per Share (7 Days)
@7%
₹53		@8%
₹60.5		@9%
₹68.1		@10%
₹75.6		@11%
₹83.2		@12%
₹90.8
About

    IPO Reservation

    CategoryShares OfferedNo. of Shares
    Retail47.5%580000
    Other47.4%578000
    Market Maker5.00%62000
    Total No. of Shares100.0%1220000

    Hamps Bio IPO Details

    Issue Size1,220,000 shares
    (aggregating up to ₹6.22 Cr)
    Fresh Issue1,220,000 shares
    (aggregating up to ₹6.22 Cr)
    Issue TypeFixed Price Issue IPO
    Listing AtBSE SME
    Share holding pre issue3,136,000
    Share holding post issue4,356,000
    Market Maker portion62,000 shares
    Market MakerPure Broking

    Key Performance Indicator

    KPIOct-24Mar-24Mar-23
    ROE16.65%21.14%30.31%
    ROCE18.53%18.31%17.43%
    RONW9.19%14.84%26.34%
    D/E0.380.311.27
    EPS (basic)1.091.761.5
    P/E Pre IPO31.94
    P/E Post IPO38.03

    Company Financials

    Hamps Bio Limited Financial Information (Restated) In Lakhs.

    PeriodOct-24Mar-24Mar-23Mar-22
    Assets644515396364
    Revenue436650558534
    Profit34503612
    Net Worth371337136101
    Reserves57141-14-49
    Borrowing138105174204

    About Company

    Hamps Bio Limited, incorporated in 2007, specializes in marketing and distributing pharmaceutical products under the "Hamps" brand and freeze-dried and frozen FMCG items under the "FzyEzy" brand. Its pharmaceutical portfolio includes tablets, syrups, capsules, injectables, and powders, distributed across eight Indian states and union territories through a network of 50+ distributors and e-commerce platforms like Amazon, Flipkart, and Jio Mart. The FMCG division offers freeze-dried and frozen products such as strawberry, mango, and beet powders, catering to both B2B and B2C markets, including contract manufacturing. With over 180 products across both segments, the company serves domestic and international markets, employing 78 people as of October 31, 2024.
    Lead Manager(s)

    Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.

    Strength

    Expert Leadership and Industry Experience: Seasoned management drives strategic growth and operational excellence.

    Expansive Distribution Network with E-Retailing: Strong presence across 50+ distributors and leading e-commerce platforms like Amazon and Flipkart.

    Diverse Product Portfolio: Offers over 180 products across pharmaceuticals and FMCG segments, catering to domestic and international markets.

    Weakness

    Outstanding Litigation: Pending legal cases could negatively impact our business, reputation, and financial performance if resolved unfavorably.

    Dependence on Third-Party Manufacturing: Reliance on external manufacturers for pharmaceutical products poses supply and quality risks.

    Single-Region Manufacturing Facility: The concentration of freeze-dried and frozen product manufacturing in Ankleshwar, Gujarat, makes operations vulnerable to regional disruptions.

    Registrar
    Bigshare Services Pvt Ltd
    Phone: +91-22-6263 8200
    Email: ipo@bigshareonline.com
    Website: https://ipo.bigshareonline.com/ipo_status.html